AZRX News and Press, AzurRx BioPharma Inc. From 01/12/21

Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infections COVID-19 GI infections are a significant unmet clinical need; AzurRx estimates potential U.S. market size of $450-600 million or greater in first year depending on how quick...

DELRAY BEACH, Fla., Jan. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced t...

DELRAY BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced t...

DELRAY BEACH, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced t...

AzurRx BioPharma (AZRX) enters into an exclusive worldwide licensing agreement with First Wave Bio for the use of their oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis (ICI-AC) and COVID-19 GI infections.According to the agr...

DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announce...

Agreement expands AzurRx’s pipeline of targeted, non-systemic GI therapies Clinical trials to initiate in 1H’21, with potential for expedited FDA 505(b)(2) pathway for IND-approved COVID-19 and breakthrough designation for immune checkpoint colitis programs ...

Why Are These 4 Penny Stocks Heating Up Right Now? Throughout 2020, there have been several shining examples of stellar penny stocks to watch . Now, obviously, we have to take into account the impact of the COVID pandemic on the stock market as a whole. Since vaccines are in dis...

Histogen HSTO -25% after pricing $14M upsized public offering.Conifer Holdings (CNFR) -10%.AzurRx BioPharma (AZRX) -12%.Novan (NOVN) -10%.SCWorx (WORX) -9%.Net Element (NETE) -8%.Professional Diversity Network (IPDN) -7%.Urban Tea (MYT) -7%.IMAC Holdings (IMAC) -7%.Abcam (ABCM) -5%....

Thinly traded nano cap AzurRx BioPharma (AZRX) perks up 9% premarket on light volume in reaction to the commencement of dosing in Turkey in an open-label Phase 2 clinical trial evaluating MS1819, combined with standard-of-care [porcine -derived pancreatic enzyme replacement therapy ...